Skip to main content
PMC home page
Gut logoLink to Gut
. 1996 Apr;38(4):623–628. doi: 10.1136/gut.38.4.623

Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid.

P T Clayton 1, K A Mills 1, A W Johnson 1, A Barabino 1, M G Marazzi 1
PMCID: PMC1383127  PMID: 8707100

Abstract

BACKGROUND--In some infants with liver disease, 3-oxo-delta 4 bile acids are the major bile acids in urine, a phenomenon attributed to reduced activity of the delta 4-3-oxosteroid 5 beta-reductase required for synthesis of chenodeoxycholic acid and cholic acid. These patients form a heterogeneous group. Many have a known cause of hepatic dysfunction and plasma concentrations of chenodeoxycholic acid and cholic acid that are actually greater than those of the 3-oxo-delta 4 bile acids. It is unlikely that these patients have a primary genetic deficiency of the 5 beta-reductase enzyme. AIMS--To document the bile acid profile, clinical phenotype, and response to treatment of an infant with cholestasis, increased plasma concentrations of 3-oxo-delta 4 bile acids, low plasma concentrations of chenodeoxycholic acid and cholic acid, and no other identifiable cause of liver disease. PATIENTS--This infant was compared with normal infants and infants with cholestasis of known cause. METHODS--Analysis of bile acids by liquid secondary ionisation mass spectrometry and gas chromatography-mass spectrometry. RESULTS--The plasma bile acid profile of the patient was unique. She had chronic cholestatic liver disease associated with malabsorption of vitamins D and E and a normal gamma-glutamyltranspeptidase when the transaminases were increased. The liver disease failed to improve with ursodeoxycholic acid but responded to a combination of chenodeoxycholic acid and cholic acid. CONCLUSION--Treatment of primary 5 beta-reductase deficiency requires the use of bile acids that inhibit cholesterol 7 alpha-hydroxylase.

Full text

PDF
625

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clayton P. T., Bowron A., Mills K. A., Massoud A., Casteels M., Milla P. J. Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology. 1993 Dec;105(6):1806–1813. doi: 10.1016/0016-5085(93)91079-w. [DOI] [PubMed] [Google Scholar]
  2. Clayton P. T., Casteels M., Mieli-Vergani G., Lawson A. M. Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: a new inborn error of bile acid synthesis? Pediatr Res. 1995 Apr;37(4 Pt 1):424–431. doi: 10.1203/00006450-199504000-00007. [DOI] [PubMed] [Google Scholar]
  3. Clayton P. T. Delta 4-3-oxosteroid 5 beta-reductase deficiency and neonatal hemochromatosis. J Pediatr. 1994 Nov;125(5 Pt 1):845–846. [PubMed] [Google Scholar]
  4. Clayton P. T., Lake B. D., Hall N. A., Shortland D. B., Carruthers R. A., Lawson A. M. Plasma bile acids in patients with peroxisomal dysfunction syndromes: analysis by capillary gas chromatography-mass spectrometry. Eur J Pediatr. 1987 Mar;146(2):166–173. doi: 10.1007/BF02343226. [DOI] [PubMed] [Google Scholar]
  5. Clayton P. T., Leonard J. V., Lawson A. M., Setchell K. D., Andersson S., Egestad B., Sjövall J. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids. J Clin Invest. 1987 Apr;79(4):1031–1038. doi: 10.1172/JCI112915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Clayton P. T., Muller D. P. A simplified gas-liquid chromatographic methods for the estimation of non-sulphated plasma bile acids. Clin Chim Acta. 1980 Aug 19;105(3):401–405. doi: 10.1016/0009-8981(80)90122-9. [DOI] [PubMed] [Google Scholar]
  7. Clayton P. T., Patel E., Lawson A. M., Carruthers R. A., Tanner M. S., Strandvik B., Egestad B., Sjövall J. 3-Oxo-delta 4 bile acids in liver disease. Lancet. 1988 Jun 4;1(8597):1283–1284. doi: 10.1016/s0140-6736(88)92104-6. [DOI] [PubMed] [Google Scholar]
  8. Daugherty C. C., Setchell K. D., Heubi J. E., Balistreri W. F. Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (delta 4-3-oxosteroid 5 beta-reductase deficiency). Hepatology. 1993 Nov;18(5):1096–1101. [PubMed] [Google Scholar]
  9. Ichimiya H., Egestad B., Nazer H., Baginski E. S., Clayton P. T., Sjövall J. Bile acids and bile alcohols in a child with hepatic 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency: effects of chenodeoxycholic acid treatment. J Lipid Res. 1991 May;32(5):829–841. [PubMed] [Google Scholar]
  10. Ichimiya H., Nazer H., Gunasekaran T., Clayton P., Sjövall J. Treatment of chronic liver disease caused by 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid. Arch Dis Child. 1990 Oct;65(10):1121–1124. doi: 10.1136/adc.65.10.1121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jacquemin E., Setchell K. D., O'Connell N. C., Estrada A., Maggiore G., Schmitz J., Hadchouel M., Bernard O. A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J Pediatr. 1994 Sep;125(3):379–384. doi: 10.1016/s0022-3476(05)83280-9. [DOI] [PubMed] [Google Scholar]
  12. Kondo K. H., Kai M. H., Setoguchi Y., Eggertsen G., Sjöblom P., Setoguchi T., Okuda K. I., Björkhem I. Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme. Eur J Biochem. 1994 Jan 15;219(1-2):357–363. doi: 10.1111/j.1432-1033.1994.tb19947.x. [DOI] [PubMed] [Google Scholar]
  13. Koopman B. J., Wolthers B. G., van der Molen J. C., Nagel G. T., Kruizinga W. Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid. Biochim Biophys Acta. 1987 Feb 14;917(2):238–246. doi: 10.1016/0005-2760(87)90128-7. [DOI] [PubMed] [Google Scholar]
  14. Koopman B. J., Wolthers B. G., van der Molen J. C., Nagel G. T., Waterreus R. J., Oosterhuis H. J. Capillary gas chromatographic determinations of urinary bile acids and bile alcohols in CTX patients proving the ineffectivity of ursodeoxycholic acid treatment. Clin Chim Acta. 1984 Sep 15;142(1):103–111. doi: 10.1016/0009-8981(84)90105-0. [DOI] [PubMed] [Google Scholar]
  15. Lawson A. M., Madigan M. J., Shortland D., Clayton P. T. Rapid diagnosis of Zellweger syndrome and infantile Refsum's disease by fast atom bombardment--mass spectrometry of urine bile salts. Clin Chim Acta. 1986 Dec 15;161(2):221–231. doi: 10.1016/0009-8981(86)90215-9. [DOI] [PubMed] [Google Scholar]
  16. Setchell K. D., Suchy F. J., Welsh M. B., Zimmer-Nechemias L., Heubi J., Balistreri W. F. Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis. J Clin Invest. 1988 Dec;82(6):2148–2157. doi: 10.1172/JCI113837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Shneider B. L., Setchell K. D., Whitington P. F., Neilson K. A., Suchy F. J. Delta 4-3-oxosteroid 5 beta-reductase deficiency causing neonatal liver failure and hemochromatosis. J Pediatr. 1994 Feb;124(2):234–238. doi: 10.1016/s0022-3476(94)70310-8. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES